Anaplastic Thyroid Cancer: BRAF-Targeted Therapy Against an Acute Airway Risk
A tumor moving fast enough to threaten her airway within days meets a drug that can act within days too — the argument is whether that timeline is a rescue or a bet the team can't take without a backup already in place.
Three weeks ago N.F. noticed a small, painless lump in her neck while getting dressed. Within ten days it had grown enough that her daughter, visiting for a weekend, insisted she see a doctor immediately rather than wait for her usual appointment. By the time she was seen, the mass had become large enough to be visibly asymmetric, and she had developed new stridor and difficulty swallowing solid food over just the past four days. A core biopsy, expedited given the pace of change, confirmed anaplastic thyroid carcinoma, and molecular testing returned positive for a BRAF V600E mutation — a dizzying sequence of events for a woman who, until three weeks ago, was a retired seamstress living independently with no prior thyroid disease of any kind.
Anaplastic thyroid carcinoma is one of the most rapidly lethal cancers in humans, historically measured in a survival of months rather than years, and this case is moving at the disease's worst pace rather than its best. Head and neck surgery, examining her this afternoon, is genuinely worried the airway could obstruct within days without intervention. Set against that timeline is dabrafenib plus trametinib, targeting her exact mutation. Its evidence comes in two tiers the team has to keep separate: the ROAR basket trial, single-arm and 36 patients, established that the combination works at all, but read response at eight weeks and says nothing about how fast shrinkage begins. The 48-to-72-hour responses being counted on here come from case reports, not from ROAR, and it is that thinner tier — fast enough, in some reported cases, to convert a high-risk airway situation into a resectable one without an emergency tracheostomy — that the argument for waiting rests on. The team's disagreement is not about whether that drug response is real; it is about whether an airway already this compromised can be trusted to survive the 48 to 72 hours the drug needs to start working, or whether the airway has to be secured first, before anything else is decided.
Her family, gathered in the hallway outside, has asked the team directly what an emergency tracheostomy would actually mean for her — whether it is a temporary bridge or a permanent change, and whether it would still leave open the possibility of the surgery that might eventually remove the tumor. Those are fair questions the team does not yet have settled answers to, because the answer depends entirely on which of the two paths below is chosen in the next hour, not on anything already decided.
Emergency multidisciplinary conference
I don't think airway safety can wait for a drug response, however promising the ROAR data are. She has new stridor and worsening dysphagia over just four days — that trajectory can obstruct completely with very little additional warning. I'd secure the airway now, before starting anything else, because a lost airway is an immediate mortality risk that no oncologic strategy afterward can undo.
I take the airway risk seriously, and I'm not proposing we ignore it — I'd point to how fast dabrafenib and trametinib have actually worked in this exact mutation. I want to be precise about where that comes from, because it matters: ROAR is what tells us the combination works, but it read response at eight weeks, so it is not my source for speed. The 48-to-72-hour shrinkage is case-report and small-series material — Subbiah's group and several others — fast enough in those reports to avert an emergent tracheostomy if started immediately with very close monitoring and surgery kept on standby.
If it works the way it has in those reports, she keeps her native airway and gets a shot at a more complete, less morbid resection once the mass has shrunk — a materially better outcome than starting from an emergency tracheostomy.
I think you're both right about different halves of this, and I don't think it has to be sequential. The drug-response data are real and fast by this disease's standards — but 48 to 72 hours is still not fast enough to bet an airway already this compromised on, with nothing in reserve if it doesn't respond as quickly as the best published cases did.
Rather than choosing between securing the airway first or starting the drug first, I'd do both today: start dabrafenib and trametinib immediately, and in parallel prepare for awake tracheostomy under local anesthesia as a same-day contingency, on standby rather than performed pre-emptively — so the airway is never left unprotected while the drug gets its best, closely monitored chance to work.
Agreed: start dabrafenib and trametinib today, with continuous pulse oximetry, hourly airway checks overnight, and the ENT team and operating room both on immediate standby for awake tracheostomy at the first sign the airway is worsening rather than improving.
Not agreed: whether this plan was the right call if the drug response turns out to be slower than the best published cases. The surgeon would have preferred securing the airway pre-emptively regardless of the drug's promise, and stated plainly that the simultaneous-hedge plan only works if the standby team is genuinely ready to act within minutes, not hours — a real operational commitment the team confirmed but did not treat as a settled disagreement resolved in the surgeon's favor or against it.